NASDAQ: KDNY

Switzerland-based pharmaceutical major Novartis (NYSE: NVS) has successfully completed the scheduled purchase of US-based kidney disease specialist Chinook Therapeutics (NASDAQ: KDNY) for a payment of $3.2 billion to its shareholders. An additional $300 million will be paid once regulatory milestones are achieved. This acquisition will enhance Novartis’s renal portfolio with…